Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort.

Medicina (Kaunas) · 2025 · PMC12654086 · PMID 41303797

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Among patients with visceral metastases, the risk of disease progression was approximately 60% higher compared with those without visceral involvement (HR: 1.60; 95% CI: 0.93–2.77; p = 0.091); however, this association did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.